Foghorn Therapeutics Q1 Revenue Plunges 45% to $3.3M, Net Loss Widens
FHTX sits 43% above its 52-week low of $3.27.
Summary
Foghorn Therapeutics reported Q1 2026 revenue of $3.3 million, a significant 45.1% decrease from the prior year, alongside a net loss of $(19.9) million, which widened from $(18.8) million in Q1 2025. Despite the increased net loss, diluted EPS improved slightly to $(0.29) from $(0.30) year-over-year. The company reiterated its cash runway, expecting current cash to fund operations for at least twelve months, a crucial detail for a clinical-stage biotech. While the report mentioned ongoing clinical progress for FHD-909 and the Lilly collaboration, these business highlights were largely known from previous filings, including the 10-K in March. The substantial decline in revenue and widening net loss are new and material financial takeaways that could negatively impact investor sentiment and the stock price. Traders will closely monitor future clinical trial developments and any potential capital raises.
At the time of this announcement, FHTX was trading at $4.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $274.7M. The 52-week trading range was $3.27 to $6.95. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.